486 related articles for article (PubMed ID: 29517082)
21. Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials.
Liu T; Wang F; Wang G; Mao H
Front Med; 2018 Jun; 12(3):340-349. PubMed ID: 29086236
[TBL] [Abstract][Full Text] [Related]
22. Benralizumab: an anti-IL-5 receptor α monoclonal antibody in the treatment of asthma.
Kupczyk M; Kuna P
Immunotherapy; 2018 Apr; 10(5):349-359. PubMed ID: 29359607
[TBL] [Abstract][Full Text] [Related]
23. Benralizumab for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype.
Al Efraij K; FitzGerald JM
Expert Rev Clin Pharmacol; 2018 Jul; 11(7):669-676. PubMed ID: 29972739
[TBL] [Abstract][Full Text] [Related]
24. A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan.
Park HS; Kim MK; Imai N; Nakanishi T; Adachi M; Ohta K; Tohda Y;
Int Arch Allergy Immunol; 2016; 169(3):135-45. PubMed ID: 27097165
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials.
Tian BP; Zhang GS; Lou J; Zhou HB; Cui W
J Asthma; 2018 Sep; 55(9):956-965. PubMed ID: 29211545
[TBL] [Abstract][Full Text] [Related]
26. Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases.
Sridhar S; Liu H; Pham TH; Damera G; Newbold P
Respir Res; 2019 Jan; 20(1):14. PubMed ID: 30658649
[TBL] [Abstract][Full Text] [Related]
27. Benralizumab: an updated treatment of eosinophilic asthma.
Cushen B; Menzies-Gow A
Expert Rev Respir Med; 2020 May; 14(5):435-444. PubMed ID: 32133878
[No Abstract] [Full Text] [Related]
28. Spontaneous resolution of atopic dermatitis incidental to participation in benralizumab clinical trial for severe, uncontrolled asthma: a case report.
Pham DN
J Med Case Rep; 2021 Mar; 15(1):103. PubMed ID: 33673870
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study.
Numata T; Miyagawa H; Nishioka S; Okuda K; Utsumi H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
BMC Pulm Med; 2020 Aug; 20(1):207. PubMed ID: 32746787
[TBL] [Abstract][Full Text] [Related]
30. Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects.
Máspero J
Ther Adv Respir Dis; 2017 Aug; 11(8):311-325. PubMed ID: 28683596
[TBL] [Abstract][Full Text] [Related]
31. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
Castro M; Wenzel SE; Bleecker ER; Pizzichini E; Kuna P; Busse WW; Gossage DL; Ward CK; Wu Y; Wang B; Khatry DB; van der Merwe R; Kolbeck R; Molfino NA; Raible DG
Lancet Respir Med; 2014 Nov; 2(11):879-890. PubMed ID: 25306557
[TBL] [Abstract][Full Text] [Related]
32. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab.
Hillas G; Fouka E; Papaioannou AI
Expert Rev Respir Med; 2020 Apr; 14(4):353-365. PubMed ID: 31958239
[No Abstract] [Full Text] [Related]
33. Matching-adjusted indirect comparison of benralizumab
Bourdin A; Husereau D; Molinari N; Golam S; Siddiqui MK; Lindner L; Xu X
Eur Respir J; 2018 Nov; 52(5):. PubMed ID: 30309978
[TBL] [Abstract][Full Text] [Related]
34. Eosinophils, the IL-5/IL-5Rα axis, and the biologic effects of benralizumab in severe asthma.
Matucci A; Maggi E; Vultaggio A
Respir Med; 2019; 160():105819. PubMed ID: 31734469
[TBL] [Abstract][Full Text] [Related]
35. Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab.
Jackson DJ; Korn S; Mathur SK; Barker P; Meka VG; Martin UJ; Zangrilli JG
Drug Saf; 2020 May; 43(5):409-425. PubMed ID: 32242310
[TBL] [Abstract][Full Text] [Related]
36. [Benralizumab: Targeting the IL-5 Receptor in Severe Eosinophilic Asthma].
Leuppi JD; Schmid-Grendelmeier P; Rothe T; von Garnier C; Simon HU; Schuoler C; Pendl G; Solèr M
Praxis (Bern 1994); 2019; 108(7):469-476. PubMed ID: 31136272
[TBL] [Abstract][Full Text] [Related]
37. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.
Emma R; Morjaria JB; Fuochi V; Polosa R; Caruso M
Ther Adv Respir Dis; 2018; 12():1753466618808490. PubMed ID: 30354852
[TBL] [Abstract][Full Text] [Related]
38. Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma.
Bourdin A; Shaw D; Menzies-Gow A; FitzGerald JM; Bleecker ER; Busse WW; Ferguson GT; Brooks L; Barker P; Gil EG; Martin UJ
J Asthma; 2021 Apr; 58(4):514-522. PubMed ID: 31859541
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma.
Matera MG; Rogliani P; Calzetta L; Cazzola M
Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):239-245. PubMed ID: 29268638
[TBL] [Abstract][Full Text] [Related]
40. Real-life experience with benralizumab during 6 months.
Padilla-Galo A; Levy-Abitbol R; Olveira C; Valencia Azcona B; Pérez Morales M; Rivas-Ruiz F; Tortajada-Goitia B; Moya-Carmona I; Levy-Naon A
BMC Pulm Med; 2020 Jun; 20(1):184. PubMed ID: 32600318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
